The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement

The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement

Abstract Cardiac remodeling involves myocardial hypertrophy and fibrosis which impairs cardiac function and, ultimately, contributes to heart failure (HF) and mortality. Fibrosis largely develops due to excessive matrix deposition and lysyl oxidase(s)-dependent collagen cross-linking. In particular,...

Full description

Saved in:
Bibliographic Details
Main Authors: Lara Perryman, Alison Findlay, Jana Baskar, Brett Charlton, Jonathan Foot, Ross Hamilton, Dieter Hamprecht, Amar Joshi, Jessica Stolp, Craig Turner, Amna Zahoor, Wenbin Zhou, Begoña López, Susana Ravassa, Arantxa González, Wolfgang Jarolimek
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Heart failure
Lysyl oxidases
LOXL2 small molecule inhibitor
Anti-fibrotic therapy
Fibrosis
Online Access:https://doi.org/10.1038/s41598-025-06312-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-06312-2

Similar Items